182 In the index

Insulin aspart ASP

A fast-acting insulin (Novolog) designed to start working quicker than regular insulin, approved for diabetes. Studies confirm it controls blood sugar faster after meals than older insulins, with the same low-blood-sugar risk as any insulin.

Also known as Novolog, Fiasp

Effects Build muscle

Routes Subcutaneous

Legal status Prescription drug

WADA Banned at all times

Molecular Structure of C₂₅₆H₃₈₇N₆₅O₇₉S₆

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C256H387N65O79S6
Molar mass: 5832
CAS: 116094-23-6
PubChem CID: 16132418

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Individualized, dosed at mealtimes (as prescribed)

Reported range Highly variable by patient

Route Subcutaneous injection

Frequency With meals, typically 3 times daily

Duration Chronic/ongoing (as prescribed)

FDA-approved rapid-acting insulin analog (NovoLog); same severe hypoglycemia risk applies to any non-medical use.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.

Variants

Name	Abbr	Route	Notes
Insulin faster aspart	FIASP	Subcutaneous	An accelerated formulation for faster onset.